The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments

Overview

Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer. With the increasing application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues concerning how are the immuno-nutrition index be altered under the effects of perioperative treatments and what are the clinical values of these index should be clarified.

Full Title of Study: “The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 1, 2020

Detailed Description

The immune (systemic inflammation) index includes: NLR (Neutrophil-to-Lymphocyte Ratio); PLR (Platelet-to-Lymphocyte Ratio); SII (Systemic Immune-Inflammation Index); GPS (Glasgow Prognostic Score); mGPS (modified Glasgow Prognostic Score); PI (Prognostic Index); The nutrition index includes: NRS2002; PNI (Prognostic Nutrition Index);

Arms, Groups and Cohorts

  • naCT
    • Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
  • naCRT
    • Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.

Clinical Trial Outcome Measures

Primary Measures

  • Pathological response
    • Time Frame: One month after surgery
    • Pathological response

Secondary Measures

  • 3-years overall survival
    • Time Frame: Three years after surgery
    • 3-years overall survival
  • 3-years disease-free survival
    • Time Frame: Three years after surgery
    • 3-years disease-free survival
  • Postoperative morbidity
    • Time Frame: One month after surgery
    • Postoperative morbidity
  • yp TNM Stage
    • Time Frame: One month after surgery
    • yp TNM Stage

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically confirmed adenocarcinoma – Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy – Diagnosed clinical advanced gastric cancer or esophagogastric cancer Exclusion Criteria:

  • Lack of immuno-nutrition data

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Shuang-xi Li, Associate Chief Surgeon – Peking University
  • Overall Official(s)
    • Jiafu Ji, M.D., Ph.D., Principal Investigator, Peking University Cancer Hospital & Institute
  • Overall Contact(s)
    • Shuangxi Li, M.D., Ph.D., lishx@hsc.pku.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.